Abstract

To observe effects of Broncho-Vaxom immunotherapy combined with trelegy ellipta on patients with chronic obstructive pulmonary disease and its influence on inflammation-related cells that can be detected in blood routine. 120 patients with stable chronic obstructive pulmonary disease were selected and divided into observation group and control group, with 60 cases in each group. The control group was given Trelegy Ellipta alone and the observation group was given Trelegy Ellipta combined with Broncho- Vaxom immunotherapy. After 3 mo of treatment, the blood routine, immune function, lung function and clinical scores were compared between the two groups and the adverse effects of drugs were recorded. After 12 mo of follow-up, the number of acute exacerbations in patients was statistically analyzed. During treatment, the total incidence rate of adverse reactions showed no statistical difference between the two groups of patients (p>0.05). Within 12 mo of follow-up, the number of acute exacerbations was (0.41±0.12) times in the observation group, which was lower than (0.61±0.25) times in control group (p<0.05). The application of Broncho-Vaxom immunotherapy combined with Trelegy Ellipta on patients with stable chronic obstructive pulmonary disease can lower the level of eosinophil in peripheral blood, regulate the immune function, improve the lung function, enhance the quality of their life and reduce the number of acute exacerbations, as well as with good safety.